Microplastics as an emerging and iatrogenic threat in the healthcare setting

People Involved

Dr Simon Calaminus S.Calaminus@hull.ac.uk
Senior Lecturer

Microplastics as an emerging pollutant in healthcare settings, focussing on the operating room.

ThrombiGlow: ‘Smart’ Multimodal Platelet Specific ‘Theranostic’ Drug Delivery Imaging Feb 1, 2017 - Jan 31, 2020
Cardiovascular diseases (CVD) including heart attacks and strokes constitute the leading cause of mortality in the UK. The pathology underlying CVD is called atherothrombosis and is a complex, multi-cellular-inflammatory disorder. Central to this is... Read More about ThrombiGlow: ‘Smart’ Multimodal Platelet Specific ‘Theranostic’ Drug Delivery Imaging.

Platelet cAMP signalling controls thrombosis through enhanced embolisation Oct 1, 2015 - Sep 30, 2018
The activation of protein kinase A (PKA) by prostacyclin inhibits platelet activation and therefore modulates arterial thrombosis. However, the role of PKA in controlling the stability of pre-existing thrombi is unclear. The stability of thrombi is r... Read More about Platelet cAMP signalling controls thrombosis through enhanced embolisation.

Is zinc a critical modulator of cyclic nucleotide signalling? Oct 1, 2019 - Dec 31, 2022
inc (Zn2+) deficiency is present in multiple conditions from obesity to cancer. However importantly Zn2+ deficiency can lead to a bleeding phenotype.In this proposal we investigate how Zn2+ is important for the control of platelet cyclic nucleotide... Read More about Is zinc a critical modulator of cyclic nucleotide signalling?.

Effect of hypoxia on prostacyclin-mediated inhibition of platelet function Jan 1, 2023 - Dec 31, 2025
Tissue hypoxia occurs in multiple cardiovascular and pulmonary conditions that have platelet activation or hyperreactivity, including myocardial infarction, stroke, chronic obstructive pulmonary disease (COPD) and sleep apnoea. However, knowledge on... Read More about Effect of hypoxia on prostacyclin-mediated inhibition of platelet function.